Work

Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e16015

Authors: Yan-Feng Zhang, An-Lin Hao, Yong-Gui Hong, Xiao-Ming Li, Wei-Min Liang, Zhi-Xin Zheng, Guang-Yi Yang, Xiao-Feng Guo, Yan-Yan Wen, Heng Cao, Cheng Le, Hua-Jie Song, Wen-Zhong Su

Institution: Anyang Tumor Hospital

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295308

Cites:

Cited by:

Related to: 10